TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25023094

Group type: EXPERIMENTAL
Intervention: Ultrasound treatment (10 sessions)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo ultrasound (10 sessions)
Number of subjects: 54
Study: 22172923

Group type: EXPERIMENTAL
Intervention: Low-frequency low-intensity electrotherapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Manual lymphatic drainage
Number of subjects: 36
Study: 20587587

Group type: EXPERIMENTAL
Intervention: Intensive glycemia treatment (target glycated hemoglobin level <6.0%)
Number of subjects: 10251

Group type: COMPARATOR
Intervention: Standard therapy for glycemia (target glycated hemoglobin level 7.0 to 7.9%)
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Fenofibrate for intensive dyslipidemia therapy (160 mg daily plus simvastatin)
Number of subjects: 10251

Group type: COMPARATOR
Intervention: Placebo plus simvastatin for dyslipidemia
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Intensive blood-pressure therapy (target systolic blood pressure <120 mm Hg)
Number of subjects: 10251

Group type: COMPARATOR
Intervention: Standard therapy for blood-pressure control (target systolic blood pressure <140 mm Hg)
Number of subjects: 10251
Study: 17386166

Group type: EXPERIMENTAL
Intervention: Medication plus PMR (PMR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Medication group (M)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PMR
Number of subjects: 30
Study: 16241873

Group type: EXPERIMENTAL
Intervention: Wireless two-way pager-based automated messaging system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 12197851

Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 2367

Group type: COMPARATOR
Intervention: TCAs
Number of subjects: 2367
Study: 10444123

Group type: EXPERIMENTAL
Intervention: TURP (transurethral resection using a standard cutting-wire loop)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TUEVAP (transurethral electrovaporization using a modified roller electrode)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TURP
Number of subjects: 0

Group type: COMPARATOR
Intervention: TUEVAP
Number of subjects: 0
Study: 7802296

Group type: EXPERIMENTAL
Intervention: Esmolol (300 micrograms/kg/min during CPB after a bolus of 2 mg/kg prior to CPB)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2107762

Group type: EXPERIMENTAL
Intervention: Valproate monotherapy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Valproate combination therapy
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 55
Study: 6756508

Group type: COMPARATOR
Intervention: Tamoxifen alone
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus CMF chemotherapy
Number of subjects: 88
Study: 31226144

Group type: EXPERIMENTAL
Intervention: Night alarm mobilisation
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Day alarm mobilisation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Night control (gentle awakening)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Day control
Number of subjects: 16
Study: 28572068

Group type: EXPERIMENTAL
Intervention: TV cooking show without portion-size cue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TV cooking show with portion-size cue
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-food TV show
Number of subjects: 0
Study: 25884187

Group type: EXPERIMENTAL
Intervention: Web-based self-help intervention Hold on, for each other with personal support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Web-based self-help intervention Hold on, for each other with automatic support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 0
Study: 23322666

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 µg/day) for 12 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Calcium and vitamin D only (Control group)
Number of subjects: 27
Study: 21293319

Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide (IVT) 4 mg/0.1 mL
Number of subjects: 31

Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (IVB) 1.25 mg/0.05 mL
Number of subjects: 31
Study: 18188512

Group type: EXPERIMENTAL
Intervention: Citalopram 20-40 mg daily
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 18246740

Group type: EXPERIMENTAL
Intervention: Single intramuscular dose of ceftriaxone (50 mg/kg, not exceeding 1 g)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Five-day azithromycin (10 mg/kg on day 1, then 5 mg/kg daily on days 2-5)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Ten-day amoxicillin/clavulanate (90/6.4 mg/kg/day in 2 doses)
Number of subjects: 104

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 104
Study: 16194624

Group type: EXPERIMENTAL
Intervention: Lisuride patches (3mg per patch, 7.0 microg lisuride/h, applied every other day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 15389177

Group type: EXPERIMENTAL
Intervention: High-intensity back school treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-intensity back school treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 11186094

Group type: EXPERIMENTAL
Intervention: 0.125 mg of brotizolam (BTZ) administered in the morning
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 8622225

Group type: EXPERIMENTAL
Intervention: Meningococcal conjugate vaccine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Licensed meningococcal polysaccharide vaccine
Number of subjects: 90
Study: 1449049

Group type: EXPERIMENTAL
Intervention: oral midazolam 0.45 mg/kg
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group without premedication
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: oral trimeprazine tartrate 2 mg/kg, methadone 0.1 mg/kg and droperidol 0.15 mg/kg
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: intramuscular midazolam 0.15 mg/kg
Number of subjects: 123
Study: 2578469

Group type: EXPERIMENTAL
Intervention: 1.2 grams of aspirin daily
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: 0.3 grams of aspirin daily
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: External pneumatic compression and low-molecular-weight dextran for three days
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight dextran (less than 500 milliliters)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight dextran (more than 500 milliliters)
Number of subjects: 135
Study: 30015577

Group type: EXPERIMENTAL
Intervention: Toothpaste
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toothpowder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mouthwash
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bottled waters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fruit juices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbonated sweet drinks and fruit juices
Number of subjects: 0
Study: 28319589

Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 97
Study: 25956838

Group type: EXPERIMENTAL
Intervention: Water Exchange (WE)
Number of subjects: 624

Group type: COMPARATOR
Intervention: Air Insufflation (AI)
Number of subjects: 624

Group type: COMPARATOR
Intervention: Carbon Dioxide (CO2)
Number of subjects: 624

Group type: COMPARATOR
Intervention: Water Immersion (WI)
Number of subjects: 624
Study: 24268034

Group type: EXPERIMENTAL
Intervention: Probiotics (VSL#3, 900 × 10^9 daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (cornstarch)
Number of subjects: 18
Study: 21972946

Group type: EXPERIMENTAL
Intervention: Maximum antiproteinuric treatment period
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo period
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Patients with overt proteinuria
Number of subjects: 32
Study: 18035566

Group type: EXPERIMENTAL
Intervention: Real Electroacupuncture (REA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham Electroacupuncture (SEA)
Number of subjects: 35
Study: 17668012

Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real-time PCR and microarrays
Number of subjects: 0
Study: 14600073

Group type: EXPERIMENTAL
Intervention: 2 microg.kg(‐1).min(‐1) hydrocortisone infusion (II)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 200‐microg bolus of GH (III)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Combination of hydrocortisone infusion (II) and GH (III) (IV)
Number of subjects: 7

Group type: COMPARATOR
Intervention: NaCl (I)
Number of subjects: 7
Study: 11726420

Group type: EXPERIMENTAL
Intervention: Inhaled milrinone (0.25, 0.5, and 1 mg/mL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: iPGI(2) (10 microg/mL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: iPGI(2) (10 microg/mL) + inhaled milrinone (1 mg/mL)
Number of subjects: 20
Study: 9221483

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg b.i.d. and amoxicillin 1 g b.i.d. for 14 days followed by lansoprazole 30 mg q.d. for 14 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Omeprazole 40 mg b.i.d. and amoxicillin 1 g b.i.d. for 14 days followed by omeprazole 20 mg q.d. for 14 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg b.i.d. and amoxicillin 1 g b.i.d. for 14 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Quadruple therapy (metronidazole 500 mg t.i.d., tetracycline 500 mg q.i.d., bismuth-subcitrate 120 mg q.i.d., and lansoprazole 30 mg for 10 days)
Number of subjects: 50
Study: 7960304

Group type: EXPERIMENTAL
Intervention: Addiction Scale (AS)
Number of subjects: 1257

Group type: EXPERIMENTAL
Intervention: Alcoholism Scale (MAC)
Number of subjects: 1257
Study: 3662908

Group type: EXPERIMENTAL
Intervention: Topical epinephrine (1.25%) applied twice daily
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Topical indomethacin (0.5%) applied three times daily
Number of subjects: 22

Group type: COMPARATOR
Intervention: Topical indomethacin placebo applied three times daily
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Topical epinephrine (1.25%)
Number of subjects: 22
Study: 29473482

Group type: EXPERIMENTAL
Intervention: PSTP
Number of subjects: 41

Group type: COMPARATOR
Intervention: EDU
Number of subjects: 41
Study: 27562221

Group type: EXPERIMENTAL
Intervention: Access therapy with PRF + 1% ALN
Number of subjects: 90

Group type: COMPARATOR
Intervention: Access therapy with PRF
Number of subjects: 90

Group type: COMPARATOR
Intervention: Access therapy alone
Number of subjects: 90
Study: 25635577

Group type: EXPERIMENTAL
Intervention: Ocriplasmin (125 µg)
Number of subjects: 652

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 652
Study: 23429555

Group type: EXPERIMENTAL
Intervention: Follow-up formula supplemented with probiotics (Streptococcus thermophilus NCC 2496, Streptococcus salivarius DSM 13084, Lactobacillus rhamnosus LPR CGMCC 1.3724) and prebiotics (Raftilose/Raftiline)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Follow-up formula alone (placebo)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Follow-up formula supplemented with probiotics and prebiotics
Number of subjects: 224
Study: 21367664

Group type: EXPERIMENTAL
Intervention: Nutri‐plate
Number of subjects: 16
Study: 18356546

Group type: EXPERIMENTAL
Intervention: tPA + TCD + 2.8 mL microS (Target)
Number of subjects: 15

Group type: COMPARATOR
Intervention: tPA + TCD (Control)
Number of subjects: 15
Study: 17201276

Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy of cardiac insufficiency
Number of subjects: 0
Study: 15268733

Group type: EXPERIMENTAL
Intervention: Sirolimus (4-8 ng/mL) plus Tacrolimus (8-12 ng/mL for 3 months, then 5-10 ng/mL)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Sirolimus (8-16 ng/mL) plus Tacrolimus (3-8 ng/mL, with tacrolimus elimination from month 3)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Sirolimus (8-16 ng/mL) plus Tacrolimus (3-8 ng/mL, with tacrolimus elimination from month 3) after protocol amendment
Number of subjects: 87
Study: 11194595

Group type: COMPARATOR
Intervention: Short bursts (5 s) without treatment (group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oral administration of propafenone 600 mg with short bursts (group B)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Prolonged bursts (30 s) without treatment (group C)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Oral administration of propafenone 600 mg with prolonged bursts (group D)
Number of subjects: 80
Study: 8922770

Group type: EXPERIMENTAL
Intervention: Tetracaine 0.5% in glucose 0.75%
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tetracaine 0.5% in glucose 7.5%
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tetracaine 0.5% in glucose 7.5% with phenylephrine 0.125%
Number of subjects: 120
Study: 1433591

Group type: EXPERIMENTAL
Intervention: Detection of bladder/sphincter dysfunction using a questionnaire
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Correlation between bladder/sphincter dysfunction and urinary tract infections
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Correlation between bladder/sphincter dysfunction and vesicoureteral reflux
Number of subjects: 310
Study: 3933287

Group type: EXPERIMENTAL
Intervention: HCFU (600 mg/day)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Tegafur (800 mg/day)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: HCFU (in patients taking drugs for more than 90 days)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Tegafur (in patients taking drugs for more than 90 days)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: HCFU
Number of subjects: 103

Group type: COMPARATOR
Intervention: Tegafur
Number of subjects: 103
Study: 31867637

Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Cigarettes (VLNC; 0.4 mg nicotine/g tobacco)
Number of subjects: 752
Study: 29680770

Group type: EXPERIMENTAL
Intervention: American clinicians' perceptions of a hypothetical White patient
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Personal responsibility of the patient
Number of subjects: 164

Group type: COMPARATOR
Intervention: French clinicians' perceptions
Number of subjects: 164
Study: 27105704

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study: 24859356

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 733

Group type: COMPARATOR
Intervention: Unfractionated Heparin
Number of subjects: 733
Study: 22471127

Group type: EXPERIMENTAL
Intervention: Acupoint sticking therapy with Xiongbai Qianlie powder
Number of subjects: 72

Group type: COMPARATOR
Intervention: Retention-enema with Ruyi Jinhuang powder plus millimeter-wave radiation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 72
Study: 20702745

Group type: EXPERIMENTAL
Intervention: Twice-weekly MMN
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Once-weekly MMN
Number of subjects: 324

Group type: COMPARATOR
Intervention: Twice-weekly IFA
Number of subjects: 324
Study: 18248852

Group type: EXPERIMENTAL
Intervention: Selective amobarbital procedures (ACA‐IAT)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Intraarterial SPECT co‐registrated to MRI
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Anterior temporal lobectomy
Number of subjects: 17
Study: 16157616

Group type: EXPERIMENTAL
Intervention: Educational intervention by general practitioners (GPs)
Number of subjects: 3186

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3186
Study: 12814712

Group type: EXPERIMENTAL
Intervention: Fluvastatin (n=1050)
Number of subjects: 2102

Group type: COMPARATOR
Intervention: Placebo (n=1052)
Number of subjects: 2102
Study: 11534421

Group type: COMPARATOR
Intervention: Unfractionated heparin (UH) administered in continuous intravenous infusion
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) - sodic dalteparine with dicumarinic afterwards
Number of subjects: 32
Study: 9342997

Group type: EXPERIMENTAL
Intervention: Discontinuation of medications
Number of subjects: 124
Study: 8441870

Group type: EXPERIMENTAL
Intervention: Sinusoidal work rate cycling (60 rpm) at 60% TV̇E followed by sinusoidally varying work rate (30-90% of TV̇E)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sinusoidal work rate cycling
Number of subjects: 19
Study: 3514688

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 0
Study: 28913927

Group type: EXPERIMENTAL
Intervention: Monophasic HA filler
Number of subjects: 72

Group type: COMPARATOR
Intervention: Biphasic HA filler
Number of subjects: 72
Study: 27592828

Group type: EXPERIMENTAL
Intervention: β‐CRX-rich orange juice (125 mL, once a day, after breakfast)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (β‐CRX removed from orange juice, 125 mL, once a day, after breakfast)
Number of subjects: 20
Study: 24118703

Group type: EXPERIMENTAL
Intervention: boceprevir plus peginterferon alfa-2b and ribavirin (BOC/PR)
Number of subjects: 2095

Group type: COMPARATOR
Intervention: peginterferon alfa-2b and ribavirin (PR)
Number of subjects: 2095

Group type: EXPERIMENTAL
Intervention: Response-guided therapy (RGT) with boceprevir plus peginterferon alfa-2b and ribavirin (BOC/PR)
Number of subjects: 2095

Group type: EXPERIMENTAL
Intervention: Response-guided therapy (RGT)
Number of subjects: 2095
Study: 22085697

Group type: EXPERIMENTAL
Intervention: 75 mg pregabalin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 150 mg pregabalin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 10 mg oxycodone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 75 mg pregabalin + 10 mg oxycodone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 21265311

Group type: EXPERIMENTAL
Intervention: Individual Motivational Interviewing (IMI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group Motivational Interviewing (GMI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Substance Abuse Awareness Seminar (SAAS)
Number of subjects: 0
Study: 18275008

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once weekly (n=21)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg once daily (n=23)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control group (Osteopenia, n=30)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: All groups (Risedronate, Teriparatide, Control)
Number of subjects: 74
Study: 16682848

Group type: EXPERIMENTAL
Intervention: 8-week telephone and mail weight management intervention
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual care intervention
Number of subjects: 26
Study: 12552193

Group type: EXPERIMENTAL
Intervention: Parker Flex-Tip tube
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard (Portex) 7.5-mm-ID endotracheal tube
Number of subjects: 80
Study: 12064847

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - 6 sessions
Number of subjects: 145

Group type: COMPARATOR
Intervention: Standard medical care (including pharmacological management and suggestions for aerobic fitness)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Both groups (CBT and standard care)
Number of subjects: 145
Study: 9952266

Group type: EXPERIMENTAL
Intervention: Remacemide hydrochloride (REM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 0
Study: 7490153

Group type: EXPERIMENTAL
Intervention: 10 mg lisinopril
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: 20 mg lisinopril
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 2246421

Group type: EXPERIMENTAL
Intervention: Orotracheal intubation
Number of subjects: 111

Group type: COMPARATOR
Intervention: Nasotracheal intubation
Number of subjects: 111
Study: 6458919

Group type: EXPERIMENTAL
Intervention: Ipratropium (40 micrograms in two puffs)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Theophylline capsules
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ipratropium + Theophylline
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 12
Study: 6436931

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 500 mg intravenously
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA), indomethacin, noramidopyrine intravenously, and acetaminophen orally during a bronchospastic attack
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 2
Study: 29848106

Group type: EXPERIMENTAL
Intervention: One Touch Verio™ (Verio) and OneTouch Verio Flex™ (Flex) with color range indicator (CRI)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: One Touch Verio™ (Verio) for T1D subjects
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: OneTouch Verio Flex™ (Flex) for T1D subjects
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (current BGM without color)
Number of subjects: 163
Study: 29901926

Group type: EXPERIMENTAL
Intervention: Side-cutting quadriceps sparing instruments
Number of subjects: 60

Group type: COMPARATOR
Intervention: Front-cutting instruments
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both instruments
Number of subjects: 60
Study: 25041619

Group type: EXPERIMENTAL
Intervention: Allogeneic living cell bioformulation with compression therapy
Number of subjects: 227

Group type: COMPARATOR
Intervention: Standard care with compression therapy
Number of subjects: 227
Study: 22943926

Group type: EXPERIMENTAL
Intervention: Single-dose delivery system (SDS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Multi-dose delivery system (MDS)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Single-dose delivery system (SDS) and Multi-dose delivery system (MDS)
Number of subjects: 48
Study: 20934572

Group type: EXPERIMENTAL
Intervention: Fenofibric acid 135 mg + Atorvastatin 40 mg + Ezetimibe 10 mg (FA + Atorva/Eze)
Number of subjects: 543

Group type: COMPARATOR
Intervention: Atorvastatin 40 mg + Ezetimibe 10 mg (Atorva/Eze)
Number of subjects: 543
Study: 18171584

Group type: EXPERIMENTAL
Intervention: One-site phacotrabeculectomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Two-site phacotrabeculectomy
Number of subjects: 80